ASCO GI 2021 | ASCO GI 2021: HER2-positive gastric cancer, POLO and key trials in progress

Lola A. Fashoyin-Aje, MD, MPH, U.S. Food and Drug Administration, outlines her top picks from this years American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium including a talk evaluating key recent milestones in the treatment of HER2-positive gastric cancers such as the DESTINY-Gastric01 study as well as the future directions in improving outcomes in HER2-positive patients. Dr Fashoyin-Aje also looks forward to hearing the final results of the POLO study evaluating olaparib in BRCA-mutant pancreatic cancer, as well as the importance of ongoing trials in progress presented this year. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).